Investigational drug · Phase 2
SRSD107
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SRSD107"
First trial start
2025
Mar 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SRSD107", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Thromboembolism
- Coronary Artery Disease (CAD)
- Peripheral Arterial Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SRSD107" as an intervention, largest first.
- A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKAPivotal-lookingRecruiting
Sirius Therapeutics Co., Ltd.Industry
NCT07140523 · 450 participants (planned) · Start Sep 16, 2025 · Primary completion Jun 30, 2026
Drug: SRSD107; enoxaparin · For: Venous Thromboembolism
Sites: Nové Město na Moravě, Czechia
- A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial DiseasePivotal-lookingRecruiting
Sirius Therapeutics Co., Ltd.Industry
NCT07318155 · 104 participants (planned) · Start Mar 11, 2025 · Primary completion Dec 2027
Drug: SRSD107; 0.9 % sodium chloride · For: Coronary Artery Disease (CAD); Peripheral Arterial Disease
Sites: Beijing, China
Sirius Therapeutics Co., Ltd.Industry
NCT07655427 · 48 participants · Start Mar 29, 2024 · Primary completion Mar 2, 2025
Drug: SRSD107; Placebo · For: Thrombus
Sites: Beijing, China
- A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy ParticipantsCompleted
Sirius Therapeutics Co., Ltd.Industry
NCT06116617 · 40 participants · Start Jan 23, 2024 · Primary completion Dec 9, 2024
Drug: SRSD107; Placebo · For: Thrombosis
Sites: Perth, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Venous Thromboembolism
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.